Novartis Raises Forecasts on Lack of Diovan Competitor

Novartis AG raised its profit and sales forecasts as generic competition for the Diovan blood-pressure medicine failed to materialize in the U.S.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.